Bosutinib launch date

Bosutinib was approved for marketing by the U.S. FDA in 2012 and was developed by Pfizer Pharmaceuticals of the United States. Bosutinib is indicated for the treatment of patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (CML) or who are taking other medications that are less effective. This drug is also used to treat patients with accelerated phase (AP) or blast phase (BP) Ph+ CML who are already taking other medications that are not responding well.

Bosutinib is an anti-tumor drug. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Because the growth of normal cells may also be affected by bosutinib, other side effects may occur. Before starting treatment, talk to your doctor about the benefits of this medicine and the possible risks of using it.

If patients have any unusual or allergic reaction to this drug or any other drug, tell the doctor. If you have any other types of allergies, such as to food, dyes, preservatives, or animals, tell your doctor. Appropriate studies have not been conducted on the relationship between age and bosutinib treatment in children 1 year oldCP Ph+ CML and in children treated with bosutinib AP Ph+ CML or BP Ph+ CML. Safety and effectiveness have not been established. Appropriate studies that have been conducted to date have not shown geriatric-specific issues that would limit the effectiveness of bosutinib in older adults. There have not been adequate studies in women to determine the risk to the baby if this medication is used during breastfeeding. Before taking this medication while breastfeeding, weigh the potential benefits against the potential risks. There are generic drugs in India, each box costs about 1 more than 1,000. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.